It has been previously demonstrated the inhibition of EZH2, MLL1, and G9a may be a strategy to impair the survival of various tumor types, underscoring their significance as critical therapeutic targets in cancer [21,22,23]. The gene discussed is KMT2A; the disease is cancer.